Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial - 03/08/11
, Brigitte Mlineritsch, MD b, Herbert Stoeger, MD c, Gero Luschin-Ebengreuth, MD c, Dietmar Heck, MD d, Christian Menzel, MD b, Raimund Jakesz, ProfMD a, Michael Seifert, MD a, Michael Hubalek, MD e, Gunda Pristauz, MD c, Thomas Bauernhofer, MD c, Holger Eidtmann, MD f, Wolfgang Eiermann, ProfMD g, Guenther Steger, MD a, Werner Kwasny, MD h, Peter Dubsky, MD a, Gerhard Hochreiner, MD i, Ernst-Pius Forsthuber, MD j, Christian Fesl, PhD k, Richard Greil, ProfMD bon behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Summary |
Background |
Analysis of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 months’ follow-up showed that addition of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free survival. We have now assessed long-term clinical efficacy including disease-free survival and disease outcomes in patients receiving anastrozole or tamoxifen with or without zoledronic acid.
Methods |
ABSCG-12 is a randomised, controlled, open-label, two-by-two factorial, multicentre trial in 1803 premenopausal women with endocrine-receptor-positive early-stage (stage I–II) breast cancer receiving goserelin (3·6 mg every 28 days), comparing the efficacy and safety of anastrozole (1 mg per day) or tamoxifen (20 mg per day) with or without zoledronic acid (4 mg every 6 months) for 3 years. Randomisation (1:1:1:1 ratio) was computerised and based on the Pocock and Simon minimisation method to balance the four treatment arms across eight prognostic variables (age, neoadjuvant chemotherapy, pathological tumour stage; lymph-node involvement, type of surgery or locoregional therapy, complete axillary dissection, intraoperative radiation therapy, and geographical region). Treatment allocation was not masked. The primary endpoint was disease-free survival (defined as disease recurrence or death) and analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00295646; follow-up is ongoing.
Findings |
At a median follow-up of 62 months (range 0–114·4 months), more than 2 years after treatment completion, 186 disease-free survival events had been reported (53 events in 450 patients on tamoxifen alone, 57 in 453 patients on anastrozole alone, 36 in 450 patients on tamoxifen plus zoledronic acid, and 40 in 450 patients on anastrozole plus zoledronic acid). Zoledronic acid reduced risk of disease-free survival events overall (HR 0·68, 95% CI 0·51–0·91; p=0·009), although the difference was not significant in the tamoxifen (HR 0·67, 95% CI 0·44–1·03; p=0·067) and anastrozole arms (HR 0·68, 95% CI 0·45–1·02; p=0·061) assessed separately. Zoledronic acid did not significantly affect risk of death (30 deaths with zoledronic acid vs 43 deaths without; HR 0·67, 95% CI 0·41–1·07; p=0·09). There was no difference in disease-free survival between patients on tamoxifen alone versus anastrozole alone (HR 1·08, 95% CI 0·81–1·44; p=0·591), but overall survival was worse with anastrozole than with tamoxifen (46 vs 27 deaths; HR 1·75, 95% CI 1·08–2·83; p=0·02). Treatments were generally well tolerated, with no reports of renal failure or osteonecrosis of the jaw. Bone pain was reported in 601 patients (33%; 349 patients on zoledronic acid vs 252 not on the drug), fatigue in 361 (20%; 192 vs 169), headache in 280 (16%; 147 vs 133), and arthralgia in 266 (15%; 145 vs 121).
Interpretation |
Addition of zoledronic acid improved disease-free survival in the patients taking anastrozole or tamoxifen. There was no difference in disease-free survival between patients receiving anastrozole and tamoxifen overall, but those on anastrozole alone had inferior overall survival. These data show persistent benefits with zoledronic acid and support its addition to adjuvant endocrine therapy in premenopausal patients with early-stage breast cancer.
Funding |
AstraZeneca; Novartis.
Le texte complet de cet article est disponible en PDF.Plan
Vol 12 - N° 7
P. 631-641 - juillet 2011 Retour au numéro
Article précédent
- The Clink of Ice (Le Bruit des Glaçons)
- Talha Burki
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- Richard A Adams, Angela M Meade, Matthew T Seymour, Richard H Wilson, Ayman Madi, David Fisher, Sarah L Kenny, Edward Kay, Elizabeth Hodgkinson, Malcolm Pope, Penny Rogers, Harpreet Wasan, Stephen Falk, Simon Gollins, Tamas Hickish, Eric M Bessell, David Propper, M John Kennedy, Richard Kaplan, Timothy S Maughan, on behalf of the MRC COIN Trial Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?